Mrinal M Gounder1, Michelle R Mahoney1, Brian A Van Tine1, Vinod Ravi1, Steven Attia1, Hari A Deshpande1, Abha A Gupta1, Mohammed M Milhem1, Robert M Conry1, Sujana Movva1, Michael J Pishvaian1, Richard F Riedel1, Tarek Sabagh1, William D Tap1, Natally Horvat1, Ethan Basch1, Lawrence H Schwartz1, Robert G Maki1, Narasimhan P Agaram1, Robert A Lefkowitz1, Yousef Mazaheri1, Rikiya Yamashita1, John J Wright1, Amylou C Dueck1, Gary K Schwartz1. 1. From Memorial Sloan Kettering Cancer Center and Weill Cornell Medical Center (M.M.G., W.D.T., N.H., N.P.A., R.A.L., Y.M., R.Y.) and Columbia University Vagellos College of Physicians and Surgeons and New York Presbyterian Hospital (L.H.S., G.K.S.), New York, and Northwell Cancer Institute and Cold Spring Harbor Laboratory, Lake Success (R.G.M.) - all in New York; Alliance Statistics and Data Center, Mayo Clinic, Rochester, MN (M.R.M.); Washington University School of Medicine, St. Louis (B.A.V.T.); M.D. Anderson Cancer Center, University of Texas, Houston (V.R.); Mayo Clinic in Florida, Jacksonville (S.A.); Yale University, New Haven, CT (H.A.D.); University Health Network Princess Margaret Cancer Centre, Toronto (A.A.G.); University of Iowa-Holden Comprehensive Cancer Center, Iowa City (M.M.M.); University of Alabama at Birmingham Cancer Center, Birmingham (R.M.C.); Fox Chase Cancer Center, Philadelphia (S.M.); Georgetown University, Lombardi Comprehensive Cancer Center, Washington, DC (M.J.P.); Duke Cancer Institute, Duke University Medical Center, Durham (R.F.R.), and Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill (E.B.) - both in North Carolina; Dayton National Cancer Institute Community Oncology Research Program, Dayton, OH (T.S.); National Cancer Institute, Bethesda, MD (J.J.W.); and the Alliance Statistics and Data Center, Mayo Clinic, Scottsdale, AZ (A.C.D.).
Abstract
BACKGROUND: Desmoid tumors (also referred to as aggressive fibromatosis) are connective tissue neoplasms that can arise in any anatomical location and infiltrate the mesentery, neurovascular structures, and visceral organs. There is no standard of care. METHODS: In this double-blind, phase 3 trial, we randomly assigned 87 patients with progressive, symptomatic, or recurrent desmoid tumors to receive eithersorafenib (400-mg tablet once daily) or matching placebo. Crossover to the sorafenib group was permitted for patients in the placebogroup who had disease progression. The primary end point was investigator-assessed progression-free survival; rates of objective response and adverse events were also evaluated. RESULTS: With a median follow-up of 27.2 months, the 2-year progression-free survival rate was 81% (95% confidence interval [CI], 69 to 96) in the sorafenib group and 36% (95% CI, 22 to 57) in the placebo group (hazard ratio for progression or death, 0.13; 95% CI, 0.05 to 0.31; P<0.001). Before crossover, the objective response rate was 33% (95% CI, 20 to 48) in the sorafenib group and 20% (95% CI, 8 to 38) in the placebo group. The median time to an objective response among patients who had a response was 9.6 months (interquartile range, 6.6 to 16.7) in the sorafenib group and 13.3 months (interquartile range, 11.2 to 31.1) in the placebo group. The objective responses are ongoing. Among patients who received sorafenib, the most frequently reported adverse events were grade 1 or 2 events of rash (73%), fatigue (67%), hypertension (55%), and diarrhea (51%). CONCLUSIONS: Among patients with progressive, refractory, or symptomatic desmoid tumors, sorafenib significantly prolonged progression-free survival and induced durable responses. (Funded by the National Cancer Institute and others; ClinicalTrials.gov number, NCT02066181 .).
RCT Entities:
BACKGROUND:Desmoid tumors (also referred to as aggressive fibromatosis) are connective tissue neoplasms that can arise in any anatomical location and infiltrate the mesentery, neurovascular structures, and visceral organs. There is no standard of care. METHODS: In this double-blind, phase 3 trial, we randomly assigned 87 patients with progressive, symptomatic, or recurrent desmoid tumors to receive either sorafenib (400-mg tablet once daily) or matching placebo. Crossover to the sorafenib group was permitted for patients in the placebo group who had disease progression. The primary end point was investigator-assessed progression-free survival; rates of objective response and adverse events were also evaluated. RESULTS: With a median follow-up of 27.2 months, the 2-year progression-free survival rate was 81% (95% confidence interval [CI], 69 to 96) in the sorafenib group and 36% (95% CI, 22 to 57) in the placebo group (hazard ratio for progression or death, 0.13; 95% CI, 0.05 to 0.31; P<0.001). Before crossover, the objective response rate was 33% (95% CI, 20 to 48) in the sorafenib group and 20% (95% CI, 8 to 38) in the placebo group. The median time to an objective response among patients who had a response was 9.6 months (interquartile range, 6.6 to 16.7) in the sorafenib group and 13.3 months (interquartile range, 11.2 to 31.1) in the placebo group. The objective responses are ongoing. Among patients who received sorafenib, the most frequently reported adverse events were grade 1 or 2 events of rash (73%), fatigue (67%), hypertension (55%), and diarrhea (51%). CONCLUSIONS: Among patients with progressive, refractory, or symptomatic desmoid tumors, sorafenib significantly prolonged progression-free survival and induced durable responses. (Funded by the National Cancer Institute and others; ClinicalTrials.gov number, NCT02066181 .).
Authors: Rashmi Chugh; J Kyle Wathen; Shreyaskumar R Patel; Robert G Maki; Paul A Meyers; Scott M Schuetze; Dennis A Priebat; Dafydd G Thomas; Jon A Jacobson; Brian L Samuels; Robert S Benjamin; Laurence H Baker Journal: Clin Cancer Res Date: 2010-08-19 Impact factor: 12.531
Authors: Marco Fiore; Françoise Rimareix; Luigi Mariani; Julien Domont; Paola Collini; Cecile Le Péchoux; Paolo G Casali; Axel Le Cesne; Alessandro Gronchi; Sylvie Bonvalot Journal: Ann Surg Oncol Date: 2009-07-01 Impact factor: 5.344
Authors: Michael C Heinrich; Grant A McArthur; George D Demetri; Heikki Joensuu; Petri Bono; Richard Herrmann; Hal Hirte; Sara Cresta; D Bradley Koslin; Christopher L Corless; Stephan Dirnhofer; Allan T van Oosterom; Zariana Nikolova; Sasa Dimitrijevic; Jonathan A Fletcher Journal: J Clin Oncol Date: 2006-03-01 Impact factor: 44.544
Authors: Veridiana Pires de Camargo; Mary L Keohan; David R D'Adamo; Cristina R Antonescu; Murray F Brennan; Samuel Singer; Linda S Ahn; Robert G Maki Journal: Cancer Date: 2010-05-01 Impact factor: 6.860
Authors: Stephen X Skapek; William S Ferguson; Linda Granowetter; Meenakshi Devidas; Antonio R Perez-Atayde; Louis P Dehner; Fredric A Hoffer; Roseanne Speights; Mark C Gebhardt; Gary V Dahl; Holcombe E Grier Journal: J Clin Oncol Date: 2007-02-10 Impact factor: 44.544
Authors: Haesun Choi; Chuslip Charnsangavej; Silvana C Faria; Homer A Macapinlac; Michael A Burgess; Shreyaskumar R Patel; Lei L Chen; Donald A Podoloff; Robert S Benjamin Journal: J Clin Oncol Date: 2007-05-01 Impact factor: 44.544
Authors: E A Eisenhauer; P Therasse; J Bogaerts; L H Schwartz; D Sargent; R Ford; J Dancey; S Arbuck; S Gwyther; M Mooney; L Rubinstein; L Shankar; L Dodd; R Kaplan; D Lacombe; J Verweij Journal: Eur J Cancer Date: 2009-01 Impact factor: 9.162
Authors: Niamh M Long; Mrinal M Gounder; Aimee M Crago; Alexander J Chou; David M Panicek Journal: Skeletal Radiol Date: 2021-03-16 Impact factor: 2.199
Authors: S Scheipl; B Liegl-Atzwanger; J Szkandera; B Rinner; C Viertler; J Friesenbichler; M Bergovec; A Leithner Journal: Orthopade Date: 2019-09 Impact factor: 1.087
Authors: Pierre Auloge; Julien Garnon; Joey Marie Robinson; Marie-Aude Thenint; Guillaume Koch; Jean Caudrelier; Julia Weiss; Roberto Luigi Cazzato; Jean Emmanuel Kurtz; Afshin Gangi Journal: Int J Clin Oncol Date: 2021-03-11 Impact factor: 3.402
Authors: Andrew J Bishop; Jace P Landry; Christina L Roland; Ravin Ratan; Barry W Feig; Bryan S Moon; Maria A Zarzour; Wei-Lien Wang; Alexander J Lazar; Valerae O Lewis; Keila E Torres; B Ashleigh Guadagnolo Journal: Cancer Date: 2020-04-28 Impact factor: 6.860
Authors: Joanna Robles; Vahakn S Keskinyan; Matthew Thompson; Joseph T Davis; David Van Mater Journal: Pediatr Hematol Oncol Date: 2020-03-04 Impact factor: 1.969